Avenanthramide compositions with improved solubility comprising 4-hydroxyacetophenone

Abstract

To provide a composition comprising an avenanthramide or an analogue thereof, exhibiting improved solubility of an avenanthramide, in particular avenanthramide A or avenanthramide L or dihydroavenanthramide D.SOLUTION: The present invention provides a composition comprising or consisting of: at least one avenanthramide selected from the group consisting of the avenanthramides A, B, C, G, H, K, L, R and mixtures of these avenanthramides; 4-hydroxyacetophenone; and at least one solvent or a mixture of solvents.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention generally comprises at least one avenanthramide or analog thereof and a 4- Compositions with improved solubility comprising or consisting of hydroxyacetophenones their cosmetic or medical uses; food, dietary supplements, cosmetics, pharmaceuticals or veterinary products Use of such compositions for preparing medicinal preparations; as well as compositions comprising such compositions. The present invention relates to a food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation. 4-Hydroxyacetophenone to improve the solubility of venanthramide or its analogues Regarding. [Background technology]

[0002] Avenanthramides (hereafter referred to as Avns or a single avenanthramide compound) Avn is a compound that is a mixture of anthranilic acid and hydroxycinnamic acid with an amide bond. It is a low molecular weight phenolic amide containing an acid moiety, and is found in both A. sativa and A. nud a is also a group of naturally occurring phenolic amides in oats. First identified as a phytoalexin produced by plants in response to exposure to pathogens Oats contain a unique group of approximately 40 different types of Avns, which It is present in both grains and leaves. The most abundant is Avn A(N-(4'-hi hydroxycinnamoyl)-5-hydroxyanthranilic acid), Avn B (N-(4'- Hydroxy-3'-methoxycinnamoyl)-5-hydroxyanthranilic acid) and A vn C(N-(3'-4'-dihydroxycinnamoyl)-5-hydroxyanthranilic acid These are amides of 5-hydroxyanthranilic acid, p-coumarin, These Avns are composed of ferulic acid and caffeine hydroxycinnamic acid, respectively. They are primarily expressed in the seeds and appear in almost all crushed fractions, but their highest concentrations are in the husks. It occurs in the outer layer of the pulp and seeds [Boz H, Czech Journal of Food Sciences, 2015, Vol. 33(No. 5): pp. 399-404]. The total content of avenanthramides (Avns) in oat grain varied with cultivar and agronomic treatment. It was found that the range was approximately 2-700 mg / kg (0.0002-0.07%) depending on the aliarova M et al., Journal of the Brazilian Che mical Society, 2015, Volume 26(No. 11), Pages 2369-2378. ].

[0003] The extraction of Avns from oats can be performed using various solvent compositions, e.g., pure or diluted Ethanol and methanol were used. The extraction procedure is carried out using, for example, naked oat, 50% aqueous ethanol, etc. under high heat. [Tong L et al., Journal of Integrative Agr iculture, 2014, vol. 13, p. 1809].

[0004] Maliarova, M. et al., Journal of the Brazilian Chemical Society, 2015, Vol. 26(11), 2369-2378 Page, Methanol, Ethanol, and the Extraction of Avns from Naked Oat Bran The efficiency of isopropanol and ethanol was compared. The optimum conditions for the highest yield of Avns were The extraction temperature was 55°C and the extraction time was 165 min.

[0005] Avenanthramide has excellent antioxidant activity both in vitro and in vivo. and cellular oxidative dysfunction and oxidative stress-related diseases, such as neurodegeneration and cardiovascular disease. Anti-inflammatory, anti-irritant, anti-atherogenic and anti-proliferative properties that may prevent or limit the development of vascular disease. Has reproductive activity and provides additional protection against skin irritation, aging, CHD and cancer Several studies have demonstrated that the application of avenanthramides in therapeutic agents is The number of cases is increasing [Perrelli A et al., Oxidative Medicine a nd Cellular Longevity, 2018, DOI:10.1155 / 2 018 / 6015351].

[0006] The antioxidant activity of Avns was similar to that of typical cereal constituents ferulic acid, gentisic acid, and p-hydroxybutyric acid. Protocatechuic acid, silyloxybenzoic acid The antioxidant activity of these compounds was found to be 10 to 30 times higher than that of vanillin, vanillic acid, and valinic acid. Avns differ in antioxidant activity, with Avn C having the highest activity, followed by Avn B and A. This is followed by vn A. Oat extracts rich in Avns showed LD Oat antioxidants lower serum cholesterol and inhibit LDL oxidation. Inhibits terol oxidation and peroxidation, potentially reducing cardiovascular risk This has been confirmed in animal studies and in human clinical trials. Consumption of these foods, not only due to their high fiber content, but also due to Avns, is associated with increased risk of colon cancer. Another study showed that Avns-rich oat extracts can reduce The compound has been shown to inhibit atherosclerosis and activation of the NF-kB transcription factor. NF-kB transcription factors are regulators of infection and inflammation [Hueseyin B oz, Phenolic Amides (Avenanthramides) in Oa ts-A Review, Czech J.Food Sci., Vol. 33, 2015(5 No., pp. 399-404.

[0007] WO2004 / 047833A1 describes a method for the study of substance P-induced release of histamine from mast cells. Inhibition and Treatment of Itch with Avenanthramide and Avenanthramide Analogues It also describes prevention.

[0008] WO2017 / 159964A1 describes an active compound for preventing or treating hearing loss. Compositions are described that include avenanthramide or its derivatives as an ingredient.

[0009] EP0157420A2 discloses avenanthramide L as a 5-lipoxygenase inhibitor. The present invention describes avenanthramides, which include compounds that are structurally related to

[0010] Lotts T et al., Experimental Dermatology, 2017, Volume 26 (No. 8): Pages 739-742 describes dihydroavenanthramide D (CAS 697 235-49-7, INCI name: Hydroxyphenylpropamidobenzoic acid; Symris How does SymCalmin®, the active ingredient provided by SymCalmin.co.jp, help treat obesity? Inhibits cellular degranulation and exerts anti-inflammatory effects through interaction with the neurokinin-1 receptor It also describes how this is possible.

[0011] Avenanthramides have potent beneficial biological activities, which may contribute to the Mido is a nutritional, It has become a valuable and extremely interesting natural active ingredient for cosmetic and health uses. is.

[0012] Therefore, they are stable and do not decompose during processing steps, storage or transportation, as well as being resistant to light and and stable to the effects of UV radiation, metal cations, air, or certain enzymes. Based on naturally occurring, well tolerated, biodegradable substances, especially for skin Novel preparations for use in skin protection and in preventing and / or treating skin diseases - Patents.com or in the food, cosmetic, pharmaceutical and veterinary industries for the development of conventional formulations. There is a continuing need and consumer demand.

[0013] Oxidative degradation and autoxidation processes play a crucial role in the stability of the preparation. Because they can destroy the desired components, Its absence would result in unpleasant or undesirable decomposition products or would adversely affect the properties of the products, such as color. This can adversely affect the physical performance characteristics and therefore often the value of the product. This is because it reduces

[0014] Avenanthramides find applications in the nutritional, cosmetic, pharmaceutical or veterinary industries. However, it has low solubility in organic, aqueous-organic or aqueous solvents. Limit their concentration in solutions that have a clear appearance or prevent them from agglomerating during storage. or precipitated, either to the compositions themselves or to the final products into which they are incorporated. Solvents are generally liquids and can be either a pure substance or two or more solvents. It may be a mixture of substances. Avenanthramide may not be dissolved due to aggregation or precipitation. in the form in which it is obtained, it is no longer present as an active substance or is present only in a lower concentration. When the avenanthramide compounds are administered, their bioavailability decreases. , especially avenanthramides A and L, have low solubility.

[0015] Solubility is important in determining whether a compound will dissolve in each tissue to achieve the desired biological or pharmacological response. or important parameters for achieving a desired concentration of an active substance or drug in the systemic circulation. The ability of poorly soluble substances to reach biologically relevant or therapeutic concentrations after administration. To reach these levels, high doses are often required. Low solubility, and most importantly Poor water solubility is a major issue encountered in the formulation development of new chemical entities as well as in generic development. Any active substance or drug to be absorbed must be dissolved at the absorption site. Poorly soluble substances have poor and variable bioavailability. For topically and orally administered drugs or active substances, Solubility determines the desired concentration or bioavailability of these compounds for a biological or pharmacological response. is the most important parameter for achieving drug absorption. The substance or active substance must be present in solution at the absorption site. The problem poses a great challenge to formulation professionals.

[0016] Therefore, in order to maintain good solubility of avenanthramide, it is necessary to reduce the amount of avenanthramide in the composition. Biologically relevant or therapeutic concentrations or bioavailability of venanthramide To achieve this, the solubility of the avenanthramide compounds must be improved. Summary of the Invention [Problem to be solved by the invention]

[0017] Therefore, the object of the present invention is to provide avenanthramides, in particular avenanthramide A or avenanthramide B. Avenathramide L or dihydroavenanthramide D exhibiting improved solubility The present invention provides compositions comprising the ramido or analogs thereof.

[0018] In particular, the aim of the present invention is to improve the solubility of avenanthramides in compositions, Thus, the beneficial biological activity or conventional pharmaceutical properties of the avenanthramide or preparation itself Natural, biodegradable, cosmetically or pharma- ceutically well tolerated, safe, does not interfere with the body In particular, the aim of the present invention is to propose a suitable, easy to use and stable material. avenanthramide A or avenanthramide L or di in a composition or a conventional formulation A natural, biodegradable, cosmetic product that can improve the solubility of hydroavenanthramide D Commercially or pharma- ceutically well tolerated, safe, easy to use, and stable The aim is to propose a substance.

[0019] Surprisingly, the solubility of the avenanthramides or their analogues, particularly the avenanthramides, Avenanthramide A or avenanthramide, which is the least soluble avenanthramide among the avenanthramides, The solubility of avenanthramide L or dihydroavenanthramide D was The results showed that the effect of acetaminophen on the expression of acetaminophen was significantly increased, especially at low concentrations. This is especially true since at least one avenanthramide analogue is a dihydroavenanthramide. This is the case when it is mid D. [Means for solving the problem]

[0020] The above object is achieved according to a first aspect of the present invention, at least one avenanthramide or analogue thereof, and 4-Hydroxyacetophenone This is achieved by providing a composition comprising or consisting of: In a second aspect, the present invention relates to the use of said composition as a cosmetic product, in particular for skin care, for the scalp. In care, hair care, nail care, or for skin conditions, intolerant and sensitive skin, Skin irritation, skin redness, wheals, pruritus (itching), skin aging, wrinkle formation, loss of skin volume, Loss of elasticity, pigmentation spots, pigmentation abnormalities, or dry skin, i.e. dry skin that requires moisturizing. For use as a dermatological cosmetic in the prevention and / or treatment of dry skin.

[0021] In a third aspect, the present invention relates to a method for treating, in particular, a skin or keratinopathy, in particular a barrier-associated inflammation. have pathogenic, immunoallergic, atherogenic, dry or hyperproliferative components in the prevention and / or treatment of skin or keratinopathy resulting in ROS generation in the prevention and / or treatment of skin diseases associated with an increase in Serum LDL cholesterol in the prevention and / or treatment of allergic reactions and coronary heart disease To reduce sterol and lipid levels, to reduce blood pressure, to increase insulin Medicinal products for use in improving insulin sensitivity and enabling control of blood glucose levels The present invention relates to the use of said composition as a

[0022] In a fourth aspect, the present invention provides a food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation. The present invention relates to the use of said composition for the preparation of a

[0023] In a fifth aspect, the present invention provides a food, dietary supplement or cosmetic product comprising a composition according to the present invention. , pharmaceutical or veterinary preparations.

[0024] Finally, the present invention relates to avenanthramide or avenanthramide (aventhrami de) analogous compounds, in particular avenanthramide A or avenanthramide L or dihydro Avenanthramide D (2-[(3-(4-hydroxyphenyl)propanoyl]amide) Benzoic acid;INCI name:Hydroxyphenylpropamidobenzoic acid;CAS697235- 49-7) relates to the use of 4-hydroxyacetophenone to improve the solubility of

[0025] The present invention is set forth in the appended claims. The present invention and preferred modifications thereof, further objects and advantages are also set forth in the following detailed description taken in conjunction with the accompanying examples and figures. This will also be apparent from the detailed description. [Brief description of the drawings]

[0026] [Figure 1] 1 is an image of a solution containing avenanthramide A.

[0027] [Figure 2a] 1 is an image of a solution containing avenanthramide L. [Figure 2b] 1 is an image of a solution containing avenanthramide L.

[0028] [Diagram 3] 1 is an image of a solution containing a blend of avenanthramides A and B.

[0029] [Figure 4] 1 is an image of a solution containing a blend of avenanthramides B, C and D.

[0030] [Figure 5a] 1 is an image of a solution containing dihydroavenanthramide D. [Figure 5b] 1 is an image of a solution containing dihydroavenanthramide D. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] In a first aspect, the present invention provides a method for producing a composition comprising the steps of: - at least one avenanthramide or analogue thereof; and - 4-Hydroxyacetophenone The present invention relates to a composition comprising or consisting of:

[0032] The first major component of the composition according to the first aspect of the present invention is at least one avenanthrene. mido or its analogues.

[0033] The phrase "at least one" when used in this document means, for example, may contain any one or more avenanthramides. Further, the phrase "at least one" when applied to a list , means any one combination of the items specified in the list.

[0034] The composition according to the first aspect of the invention comprises the specified components described in more detail below. It is prepared by combining the following:

[0035] In the context of the present invention, the term "avenanthramide" (anthranilic acid amide) means Among them, members of the group of phenolic alkaloids, mainly Avena sativa), as described in detail hereinafter. Cabbage white butterfly eggs (Pieris brassicae and P. rapae) and It is also present in fungal-infected carnations (Dianthus caryophyllus). The naturally occurring aventhramides, or Non-naturally occurring, artificially produced avenges, as described in more detail below. It is believed to mean a ramido analogue.

[0036] The avenanthramides of the compositions of the present invention are naturally found and are enriched, isolated, and purified from oats. The two main species of oat are Avena sativa L. . and Avena nuda L. (synonyms: Gillet and Magn Avena sativa subsp. nuda (L.) by e, and Koern Avena sativa var. nuda (L.) by The highest concentrations appear to be in the peripheral regions, husks, trichomes or straw. A large number of distinct avenanthramides have been isolated from oat kernels [Colli ns, Journal of Agricultural and Food Chem. istry, vol. 37 (1989), pp. 60-66].

[0037] Avns can be represented by the following general formula 1: [ka]

[0038] Table 1 below shows examples of naturally occurring Avns based on general formula 1.

[0039] [Table 1]

[0040] Several studies have shown that avenanthramides have anti-inflammatory, antioxidant, anti-itch, anti-irritant and It has been demonstrated that it has anti-atherogenic and anti-inflammatory activity.

[0041] Naturally occurring avenanthramides or mixtures of avenanthramides as described above The invention relates to an extract from a plant of the genus Avena, in particular any oat species, fresh or dried. or parts thereof, for example Avena sativa or Avena nuda Crushed kernels, uncrushed kernels, husks, trichomes or oothecae It can be obtained, enriched and isolated from barley straw.

[0042] The extraction solvent (extractant) for extracting avenanthramide L is a mixture of water and an organic solvent. The organic solvent is preferably selected from the group consisting of foodstuffs, cosmetic or pharmaceutical preparations. It goes without saying that such solvents may be suitable for food, cosmetic or pharmaceutical products. It must be suitable and compatible with the preparation of the formulation.

[0043] In a more preferred variant, the extraction solvent comprises a mixture of water and alcohol or acetone. The alcohol is preferably methanol, ethanol, n-propanol, isopropanol. , n-butanol, isobutanol, t-butanol and mixtures thereof, i.e. The most preferred extraction solvents for the extraction step of the present invention are selected from the group consisting of The extractant is methanol, ethanol, n-propanol, isopropanol or acetone. tonnes, or any mixture of said solvents, each in admixture with water. The use of pure organic solvents is not favored by the simultaneous extraction of triglycerides.

[0044] The ratio of water to organic solvent in the extraction solvent, preferably the ratio of water to alcohol, The mixture ratio of acetone to water or the mixture ratio of acetone to water was determined based on the extraction solvent produced. , in the range of 10:90 to 90:10 (v / v), preferably 20:80 to 80:20 (v / v), and most preferably in the range of 30:70 to 70:30 (v / v). do.

[0045] Particularly preferred extraction solvents (extractants) are methanol / water (3:7), methanol / water (1 :1), methanol / water (7:3), ethanol / water (3:7), ethanol / water (1: 1), ethanol / water (1:4), ethanol / water (7:3), isopropanol / water ( 3:7), isopropanol / water (1:1), isopropanol / water (7:3), acetonitrile The mixtures used were acetone / water (3:7), acetone / water (1:1), and acetone / water (7:3).

[0046] To improve the extraction yield, the oat source is heated at 30 to 80°C, preferably 40 to 70°C. The extract is made from crushed oat kernels at a temperature in the range of 50-60°C. The extraction yield increases with increasing temperature between 40 and 70°C.

[0047] Apart from the avenanthramide compounds enriched, isolated, and purified from natural sources, Naturally occurring avenanthramides can be produced by organic synthesis. Methods for the synthesis of the compound are described, for example, in U.S. Pat. No. 6,096,770 and U.S. Pat. No. 6,127, ,392, Japanese Patent No. J60019754A and Hungarian Patent No. HU20099 An example is given in No. 6B.

[0048] The synthetic avenanthramide substances prepared above were the same as the corresponding avenanthramide substances isolated or extracted from oats. It is identical to the naturally occurring avenanthramide compound.

[0049] Formula 2 below: [ka] (wherein m=0, 1, 2 or 3; p=0, 1 or 2; n=0, 1 or 2, However, when n=1 or 2, p+m>0, R when n=1 or 2 1 and R 2 represents H for each pair. or together with other chemical bonds (e.g., as cinnamic acid derivatives), When m=1, 2, or 3, each X independently represents OH, Oalkyl, or Oacyl. Represents, When p=1 or 2, each Y independently represents OH, Oalkyl, or Oacyl. , If p+m>0, then at least one of X and Y is selected from the group consisting of OH and O acyl. provided that the compound is selected from the group consisting of R 3 is -H or alkyl (especially -CH3 or other alkyl groups having 2 to 30 carbon atoms). In this context, R 3 The corresponding pharmacologic approved (also -H for acceptable salts) and have important biological properties, hereinafter referred to as "similar compounds." In the compositions according to the present invention, the avenanthramide compound is also called an avenanthramide compound or an analog avenanthramide compound. Non-naturally occurring avenanthramide analogs are described, for example, in WO2004 / 047833A1 or or artificially produced by the organic synthesis method disclosed in WO2007 / 062957A1.

[0050] Particularly preferred compounds of formula 2 according to the invention are n=1 or 2 and p+m>0, and / or p+m>0, and at least one of X or Y or X and Y is OH and O The compound is selected from the group consisting of alkyl.

[0051] Particularly preferably, n=1 and p+m>2, provided that at least one of X and Y and the two of formula 2 are selected together from the group including OH and Oalkyl. A compound is used.

[0052] n=1 and m=1, 2 or 3, with the proviso that at least one X is OH and Oalkyl, and / or P=1 or 2, with the proviso that at least one Y is selected from the group consisting of OH and Oalkyl. It is also preferred to use a compound of formula 2

[0053] If n has the value 1, then R 1 and R 2 are each preferably H, with the proviso that R 1 and R 2 can also combine into other chemical bonds.

[0054] Formula 2 and WO2004 / 047833A1 or WO2007 / 062957A1 With respect to the definition of the specific avenanthramide compounds disclosed, the corresponding disclosures in the above documents are The disclosure is incorporated herein by reference.

[0055] The avenanthramide analog compound of formula 2 is preferably [ka] [ka] [ka] [ka] is selected from the group consisting of:

[0056] The above examples essentially relate to compounds of formula 2 where n=1.

[0057] However, the use of compounds of formula 2 where n=0 is also often preferred, in which case m+ p=0 or m+p>1 or 2, with the proviso that among the substituents X and Y, are selected from the group consisting of OH and Oalkyl. is preferred.

[0058] [ka] [ka] [ka] It is particularly preferred to use compounds of formula 2 (n=0) selected from the group comprising:

[0059] Particularly preferred are the compounds represented by these structural formulas, in which R 3 is always H be.

[0060] Instead of these preferred compounds, in each case, R 3 is CH3, or Use the corresponding compounds, which are linear or branched alkyl with 2 to 30 C atoms. It is also preferable to

[0061] From the above avenanthramide analogues, compound No. 8 (dihydroavenanthramide D(2- [(3-(4-hydroxyphenyl)propanoyl]amido)benzoic acid; INCI name: Hydroxyphenylpropamidobenzoic acid; CAS 697235-49-7) and No. 2 7 is particularly preferred.

[0062] In addition to the naturally occurring avenanthramides and non-naturally occurring avenanthramide analogs described above, , N-(4'-hydroxycinnamoyl)-3-hydroxyanthranilic acid (YAvn I) and N-(3'-4'-dihydroxycinnamoyl)-3-hydroxyanthranilic Novel avenanthramide analogues, including avenanthramide acid (YAvn II), are produced in recombinant yeast. These encode the main proteins involved in the biosynthesis of phenolic esters. Two plant genes (4cl-2 from tobacco and hc from artichoke) Engineering Saccharomyces cerevisiae strains using Notably, YAvn I and YAvn II were generated by They share structural similarities with Avn A and Avn C, respectively.

[0063] In the context of the present invention, naturally occurring avenanthramides obtained from natural sources or synthetically produced The naturally occurring avenanthramides that are preferred are also used.

[0064] The term "avenanthramide or an analog thereof" refers to the various isomers that exist. , especially the (naturally occurring) trans-isomer as well as the cis-isomer, e.g., upon exposure to light cis-isomerized double bonds (formula 1 or 2 with n=1) induced by photoisomerization with or one or two cis-isomeric double bonds (formula 1 or 2 with n=2) The term is also intended to include avenanthramides, which have the same properties as those of the benzodiazepines.

[0065] In particular, within the context of the present invention, avenanthramides are represented by the general formula 1 and defined in Table 1. avenanthramide compounds, or any isomer or The avenanthramide analogues are represented by the general formula 2 and its definitions: or any one of its isomers as described above. do.

[0066] In a preferred variant of the invention according to the first aspect, the composition comprises avenanthramides A, B, At least one avenanthrami selected from the group consisting of C, G, H, K, L and R and even more preferably avenanthramide A or avenanthramide L.

[0067] In a preferred variant of the invention according to the first aspect, the composition comprises at least avenanthramide Includes the analog compound dihydroavenanthramide D.

[0068] In another variation, the composition of the present invention comprises avenanthramides A, B, C, G, H, K, L ( Non-Collins abbreviation; CAS number 172549-38-1) (also called O or 2pd) and R, Therefore, a combination / mixture of avenanthramides includes a It may contain any of the following combinations of venanthramide: A / B; A / C; A / G. ;A / H;A / K;A / L;A / R;B / C;B / G;B / H;B / K;B / L;B / R ;C / G;C / H;C / K;C / L;C / R;G / H;G / K;G / L;G / R;H / K ;H / L;H / R;K / L;K / R;L / R;A / B / C;A / B / G;A / B / H;A / B / K;A / B / L;A / B / R;A / C / G;A / C / H;A / C / K;A / C / L ;A / C / R;A / G / H;A / G / K;A / G / L;A / G / R;A / H / K;A / H / L;A / H / R;A / K / L;A / K / R;A / L / R;B / C / G;B / C / H;B / C / K, B / C / L;B / C / R;C / G / H;C / G / K, C / G / L;C / G / R , G / H / K;G / H / L;G / H / R;H / K / L, H / K / R;K / L / R;A / B / C / G;A / B / C / H;A / B / C / K;A / B / C / L;A / B / C / R;A / C / G / H;A / C / G / K;A / C / G / L;A / C / G / R;A / G / H / K;A / G / H / L;A / G / H / R;A / H / K / L;A / H / K / R;A / K / L / R;B / C / G / H;B / C / G / K;B / C / G / L;B / C / G / R;C / G / H / K;C / G / H / L;C / G / H / R;G / H / K / L;G / H / K / R and H / K / L / R.

[0069] However, the most preferred mixtures of avenanthramides according to the present invention are A / B, A / C, A / L , B / C and A / B / C.

[0070] In addition to the above avenanthramide compounds or avenanthramide combinations, the composition also includes avenanthramide. Insuramides A, B, C, G, H, K, L (non-Collins abbreviations; CAS number 172549-3 8-1) (also called O or 2pd) and one or more avenans other than R avenanthramides, e.g., avenanthramides D, E, FU, X, Y (also called 2), AA, CC or OO or any of the remaining avenanthramide compounds identified in Table 1. It can be included in the following:

[0071] In another variation, the composition of the present invention comprises avenanthramides A, B, C, G, H, K, L ( Non-Collins abbreviation; CAS number 172549-38-1) (also called O or 2pd) and R, i.e., one, two or more More avenanthramide was synthesized by the avenanthramide analogue dihydroavenant. Avenanthramide D is included in the mixture. It may contain one of the following: A / dihydroavenanthramide D; B / dihydroavena Avenanthramide D;C / Dihydroavenanthramide D;G / Dihydroavenanthramide D;H / Dihydroavenanthramide D;K / Dihydroavenanthramide D;L / Dihydroavena avenanthramide D; or R / dihydroavenanthramide D; A / B / dihydroavenanthramide A / C / Dihydroavenanthramide D; A / D / Dihydroavenanthramide D; A / G / Dihydroavenanthramide D; A / H / Dihydroavenanthramide D; A / K / Dihydroavenanthramide D;A / L / Dihydroavenanthramide D;A / R / Dihydro Avenanthramide D;B / C / Dihydroavenanthramide D;B / D / Dihydroavenant Avenanthramide D;B / G / Dihydroavenanthramide D;B / H / Dihydroavenanthramide D;B / K / Dihydroavenanthramide D;B / L / Dihydroavenanthramide D;B / R / Dihydroavenanthramide D; C / D / Dihydroavenanthramide D; C / G / Dihy Droavenanthramide D;C / H / Dihydroavenanthramide D;C / K / Dihydroavenanthramide Nanthramide D;C / L / Dihydroavenanthramide D;C / R / Dihydroavenanthramide dihydroavenanthramide D; G / H / dihydroavenanthramide D; G / K / dihydroavenanthramide D; G / L / Dihydroavenanthramide D; G / R / Dihydroavenanthramide D; H / K / Dihydroavenanthramide D;H / L / Dihydroavenanthramide D;H / R / Dihydro Avenanthramide D;K / L / Dihydroavenanthramide D;K / R / Dihydroavenant or a combination of L / R / dihydroavenanthramide D. Even more preferred A / dihydroavenanthramide D or avenanthramide L / dihydroavenanthramide It may contain mid D.

[0072] In addition to the above avenanthramide combinations, the composition also contains avenanthramides A, B, C, G, H, K, L (non-Collins abbreviations; CAS number 172549-38-1) (with O or 2pd) (also referred to as R) and one or more avenanthramides other than R, e.g., avenanthramide Mid D, E, FU, X, Y (also called 2), AA, CC or OO or as specified in Table 1 Any of the remaining avenanthramide compounds listed above and dihydroavenanthramide D The composition may further include a combination of

[0073] In another variation, the composition of the invention comprises one avenanthramide analog compound, preferably Dihydroavenenthramide D, or an avenanthramide analogue compound, preferably dihydroavenanthramide D, and generally Any one or more different avenanthrami represented by formula 2 and identified above. This includes combinations with analogous compounds.

[0074] At least one avenanthramide or avenanthramine as described above. avenanthramide or a mixture of avenanthramide analogues The substance is present in the composition at a concentration of 0.0001 to 5.0% by weight based on the total weight of the composition. In a preferred variant, the composition comprises at least one avenanthramide. or avenanthramide analogue compound or avenanthramide or avenanthramine A mixture of doped analogue compounds is added at a concentration of 0.0005 to 2.0% by weight based on the total weight of the composition. and more preferably, at a concentration or total amount of 0.001 to 1.0% by weight. include.

[0075] The second major component of the composition according to the first aspect of the present invention is a 4-hydrogen peroxide represented by formula 3: Hydroxyacetophenone (INCI name: Hydroxyacetophenone; CAS 99-93-4) Or p-hydroxyacetophenone. [ka]

[0076] 4-Hydroxyacetophenone is a nature-identical ingredient. It is synthetically produced. It is manufactured in plants and is also found naturally in Norwegan spruce trees.

[0077] In cosmetic or pharmaceutical preparations, 4-hydroxyacetophenone is used as a synthetic antioxidant and It is a skin conditioning ingredient. Certain antioxidant compounds are actually p-hydroxyacetones. Known as tofenone, it neutralizes several different types of free radicals. Its secondary benefit is to strengthen preservative systems in cosmetic products. This allows cosmetic chemists to reduce allergy reactions without losing efficacy. It is possible to use lower amounts of preservatives with the benefit of reducing the risk of reaction. 4-Hydroxyacetophenone may also cause symptoms of irritation. It also has soothing properties because it can inhibit an enzyme on the surface of the skin (known as COX-2). In addition, the product contains FEMA / GRAS listed Nature Identifiable Ingredients. It exhibits excellent stability at high and low pH levels and temperatures. Hydroxyacetophenone is easy to formulate, and it is suitable for low temperature process formulations, e.g. Good for shampoos, wet wipes and lotions; low odor and colorless The compound is suitable for oral use because it is soluble in ethanol and glycol and has a food grade In addition, 4-hydroxyacetophenone is added to improve solubility. As compounds, for example compounds for improving the solubility of flavours and fragrances, in particular Compounds for dissolving lipophilic compounds, such as those described in EP 2962678 A1; However, because the substances differ in their chemical properties, It is not possible to simply generalize the effect of one compound in combination with another substance to apply to other compounds. I can't.

[0078] Surprisingly, the combination of 4-hydroxyacetophenone resulted in one avenging avenanthramide or more avenanthramide or avenanthramide Avenanthramide or avenance in a solvent or composition containing a venanthramide analogue It turns out that this is beneficial for improving the solubility of the ramido analogues. Depending on the concentration, 4-hydroxyacetophenone can form one avenanthramide or more Many avenanthramides or one avenanthramide analogue compound or more The avenanthramide analogue compound can even be completely dissolved.

[0079] More surprisingly, 4-hydroxyacetophenone e) was the lowest among avenanthramides or avenanthramide analogs, respectively. Avenanthramide A or Avenanthramide L or Dihydroavenanth with solubility It turned out to be particularly effective in increasing the solubility of Ramid D.

[0080] The compound for improving solubility is a compound that improves the solubility of a solvent or another poorly soluble component in the composition or to improve the solubility of a substance and to prevent aggregation or precipitation of said components or substances. It means a compound used to increase the solubility of poorly soluble components or substances. By applying the mixture, the component can be adjusted to its desired concentration in the solvent or composition in which it is incorporated, or or its bioavailability for a biological or pharmacological response. Furthermore, by increasing the solubility of poorly soluble components or substances, said solubility It is possible to stabilize liquid compositions or solutions containing components or substances with low stability during storage. can.

[0081] Thus, in the context of the present invention, 4-hydroxyacetophenone is a compound in a solvent or composition. , to improve the solubility of the active ingredient, i.e., one or more avenanthramides, and thus and the bioavailability of the active substances in the compositions or final products in which they are incorporated. It is a substance used to increase

[0082] Add 4-hydroxyacetophenone By this, the solubility of avenanthramide can be significantly increased, i.e., avenanthramide can be dissolved in water. The avenanthramides do not aggregate or precipitate. The liquid composition solution containing the compound can be stabilized during storage. This effect is shown in the following examples. It is demonstrated that the addition of 4-hydroxyacetophenone results in a clearer solution with less precipitate. Drop.

[0083] The total amount of 4-hydroxyacetophenone present in the composition according to the invention is the total amount of the composition. It can be between 0.005 and 2.0% by weight based on weight. In a preferred variant, The concentration of all stabilizers in the composition is 0.01 to 1.5% by weight, based on the total weight of the composition. More preferably, between 0.1 and 1.0% by weight based on the total weight of the composition. It can be.

[0084] The concentration of 4-hydroxyacetophenone present in the composition according to the invention is at most 0. Between 1 and 1.0% by weight is preferred: the composition is clear and not cloudy. This means that the sulamide is completely dissolved in the composition.

[0085] As will be apparent from the following examples, 4-hydroxyacetophenone may be one or more The solubility of avenanthramide can be effectively improved. At a concentration of 0.01% by weight, 4-hydroxyacetophenone can be used in one or more The dissolution of avenanthramides, especially avenanthramide A At a concentration of 0.50% by weight, 4-hydroxyacetophenone has already improved solubility. The above concentrations completely dissolve one or more avenanthramides even at low concentrations. Depending on the concentration, hydroxyacetophenones are usually used as antioxidants in cosmetic or pharmaceutical preparations. It is used as a sterilizing or antibacterial agent.

[0086] Particularly preferred mixtures according to the invention are those in which the composition comprises, based on the total weight of the composition: 0.0001 to 5.0% by weight, in particular 0.0005 to 2.0% by weight, even more preferably or 0.001 to 1.0% by weight of at least one avenanthramide or its analogue ; and - 0.005 to 2.0% by weight, in particular 0.01 to 1.5% by weight, even more preferably 0 .1 to 1.0% by weight of 4-hydroxyacetophenone, It is a mixture comprising or consisting of:

[0087] The good solubility is achieved when at least one avenanthramide is present in the composition according to the invention in the form of a 4- To hydroxyacetophenone, a ratio of 1:1 to 1:50; more preferably 1:1. 5 to 1:40 ratio, or at least one avenanthramide analogue, especially and dihydroavenanthramide D in a ratio of 1:0.2 to 1:30, especially 1:0.5 to 1:20. This is particularly achieved when present at 100° C., as demonstrated by Table 8. The appearance of the composition is good. Thus, the avenanthramide or avenanthramide analog compounds do not aggregate or precipitate.

[0088] The compositions according to the invention, which are particularly preferred, are characterized as comprising avenans. avenanthramide or avenanthramide analogue compounds, particularly avenanthramide A, avenanthramide The composition according to the present invention has good solubility of dihydroavenanthramide L or dihydroavenanthramide D. The solubility is surprisingly high for single or multiple acetophenones, with only 4-hydroxyacetophenone missing. The composition is superior to compositions containing a number of avenanthramide or avenanthramide analogue compounds. Cosmetically or medicamentously active substances, i.e. substances with very interesting biological merits, For example, they exhibit anti-inflammatory, antioxidant, anti-itch, anti-irritant and anti-atherogenic activity. Avenanthramide or avenanthramide analogues, particularly dihydroavenanthramide D, does not aggregate or precipitate, and is therefore available in therapeutically effective amounts for longer, thus The AF-2000 will reach targeted targets better.

[0089] The compositions according to the invention are also particularly effective and are effective in preventing any toxicological or dermatologically significant The composition does not contain any secondary components. Therefore, the composition is not useful in cosmetic or pharmaceutical preparations. can be used without further concern.

[0090] The composition according to the invention may be prepared by: It can be prepared in the form of a liquid composition having improved solubility, or as an individual composition. The constituents are added separately to the final formulation, and at least one of the avenanthramides or can improve the solubility of the avenanthramide analog compounds.

[0091] 4-Hydroxyethyl ether is used in the composition and final preparation in a concentration range relevant for activity and administration. In the concentration range relevant for activity and administration, - Toxicologically acceptable; - Well tolerated by the skin, - stable (especially in conventional formulations); - preferably odorless, and - It can be produced cheaply (i.e. using standard processes and / or Starting from standard precursors) Please keep this in mind.

[0092] In combination with the above-mentioned properties of 4-hydroxyacetophenone, Anti-inflammatory, antioxidant, antipruritic, anti-irritant and anti-inflammatory properties of avenanthramide or avenanthramide analogues and antiatherogenic activity, which may provide avenous and / or pharmacological responses. to provide a desired concentration or bioavailability of the avenanthramide or avenanthramide analog. Thus, the composition according to the invention is useful for skin protection and for the prevention and / or treatment of skin diseases. It is beneficial for the placement.

[0093] Thus, another aspect of the present invention relates to the use of a composition according to the first aspect of the present invention as a cosmetic agent. Use, especially in skin care, scalp care, hair care, nail care, or for skin conditions, Skin irritation, skin redness, wheals, pruritus (itching), skin aging, formation of wrinkles, loss of skin volume, loss of skin elasticity, pigmented spots, pigmentation abnormalities, or dry skin, i.e. Use as a cosmetic in the prevention and / or treatment of dry skin requiring skin moisturization. Regarding.

[0094] Another aspect of the invention relates to a composition according to the first aspect of the invention for use as a medicament. do.

[0095] Due to its excellent properties as described above, the composition according to the first aspect of the present invention is suitable for treating skin diseases or corneal ulcers. Interstitial diseases, especially barrier-related, inflammatory, immunoallergic, atherogenic, dry Prevention and / or treatment of skin or keratinopathy having a cutaneous or hyperproliferative component in the treatment or prevention and / or treatment of cardiovascular disease, allergic reactions, coronary heart disease or in treatment to reduce serum LDL cholesterol and lipid levels. To improve insulin sensitivity, reduce blood pressure, and regulate blood sugar levels. This is particularly useful for enabling control.

[0096] Due to the specific antioxidant activity of avenanthramides, the present invention also aims to A composition according to the first aspect of the invention for use in the prevention and / or treatment of skin diseases. Also relates to.

[0097] Examples of such skin or keratin disorders include eczema, psoriasis, seborrhea, dermatitis, erythema, and acupuncture. Pruritus (itching), otitis, inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune bullous, urticarial, angiodermal and allergy-related diseases These include allergic skin reactions, and wound healing, as well as skin diseases associated with increased ROS generation. Examples of diseases include atopic dermatitis, neurodermatitis, psoriasis, rosacea, acneiform eruptions, asteatosis and Xerosis is selected from the group consisting of:

[0098] In a particularly preferred variant of the invention, at least one avenanthramide according to the invention is also The compositions comprising or consisting of the compound or its analogues are useful for preventing and / or treating pruritus (itch). Or useful to provide a benefit in treatment.

[0099] Chronic pruritus is a common symptom associated with a variety of skin conditions and systemic diseases and may Chronic pruritus is characterized by clinical symptoms (e.g., inflammatory / inflammation) and therefore no known underlying condition. Combined with the presence of inflammatory or normal / non-inflammatory skin and / or secondary scratch lesions and underlying causes (e.g., dermatologic, systemic, neurological, psychosomatic, mixed or They are classified according to their origin (uncertain origin).

[0100] The use of avenanthramide or its analogues for each of these purposes is The therapeutic activity of each of the active substances is enhanced by adding an effective amount of the active substance or composition. It corresponds to a method for granting.

[0101] In the context of the present invention, an effective amount of a composition is defined as the amount of each active ingredient, i.e., avenin and providing a benefit, e.g., a reduction in symptoms associated with the disorder, disease, or condition being treated. When applied to a combination or composition, as in the present invention, , the term refers to the amount of combined active ingredients that provides a benefit.

[0102] Thus, the present invention relates to a method for treating a skin disease or keratinopathy, particularly a keratinopathy, in a subject in need thereof. In particular, barrier-related inflammatory, immunoallergic, atherogenic, dry or hypertensive Preventing and / or treating skin or keratinopathy having a hyperproliferative component or for the prevention and / or treatment of cardiovascular disease, allergic reactions, coronary heart disease for reducing serum LDL cholesterol and lipid levels in To reduce blood sugar levels, improve insulin sensitivity, and allow for blood sugar control The method comprises administering to a subject a skin or keratinopathy, particularly a barrier-related inflammation. have pathogenic, immunoallergic, atherogenic, dry or hyperproliferative components , prevention and / or treatment of skin or keratinous diseases, or cardiovascular diseases, allergies, In the prevention and / or treatment of hypercalcaemia, hypercalcaemia, hypercalcaemia, and hypercalcaemia, and in the prevention and / or treatment of coronary heart disease, Insulin, for reducing steroid and lipid levels, for reducing blood pressure at least in sufficient amounts to improve sensitivity and to allow control of blood glucose levels; Contains one avenanthramide or its analogue and 4-hydroxyacetophenone or a method comprising administering a therapeutically effective amount of a composition comprising the same.

[0103] Due to its remarkable action as described above, the composition according to the first aspect of the invention Advantageously suitable for the preparation of food, dietary supplement, cosmetic, pharmaceutical or veterinary preparations.

[0104] The compositions according to the invention may be used in combination with conventional food, dietary supplement, cosmetic, pharmaceutical or veterinary preparations. can be easily incorporated into

[0105] Thus, a further aspect of the present invention is a food product, a dietary supplement, comprising a composition according to the present invention. In a preferred embodiment of the invention, the composition comprises The functional food containing the above-mentioned ingredient may be used for skin care and / or to prevent the above-mentioned skin disorders or keratin disorders. It is provided as an active ingredient for the purpose of recovery.

[0106] In a preferred variant, the food, nutritional supplement, cosmetic, pharmaceutical or veterinary preparation is 0.0001 to 5.0% by weight, preferably 0.0005 to 2.0% by weight, The composition according to the present invention is preferably contained in an amount of 0.001 to 1.0% by weight.

[0107] Within this context, it is also possible to combine the compositions according to the invention with other active compounds, e.g. other synergistically enhancing substances. For example, anti-inflammatory, antibacterial or antifungal substances, redness-relieving or itching-relieving effects. substances having therapeutic properties, analgesic substances, moisturizing and / or cooling agents and / or antioxidants , preservatives, (metal) chelating agents, penetration enhancers, and / or the like as described in more detail below and Combined with cosmetically or pharma- ceutically acceptable excipients as exemplified. It is also possible, and in some cases advantageous, to

[0108] An active agent is a substance or agent that confers a primary utility to a composition or preparation / conventional formulation. Examples of such active substances include antioxidants, preservatives, (metal) chelates, etc. Excipients are substances that are added to cosmetics as a result of processing or manufacturing. Or it refers to an inactive substance used to formulate a medicine.

[0109] Skin conditions or diseases are often characterized by dry skin, scratchy skin, skin lesions or Furthermore, it is accompanied by inflammation, and the composition or cosmetic and / or pharmaceutical preparation according to the present invention Particularly advantageously, the composition contains skin moisturizing and / or moisture-retaining substances, cooling agents, osmolytes, keratinizing agents, etc. Solubilizing agents, nutritional agents, anti-inflammatory agents, antibacterial or antifungal agents, and / or redness relief agents The composition contains substances that have an antipruritic or anti-itching effect and / or analgesic substances.

[0110] Itching occurs with particular intensity when the skin is dry. Skin moisturization and / or hydration Use of retention substances or conditioning agents in cosmetic and pharmaceutical preparations significantly reduces itching Thus, the cosmetic or pharmaceutical preparation according to the invention can also comprise one or Particularly advantageously in combination with a number of skin moisturizing and / or moisture retaining substances or conditioning agents. The cosmetic or pharmaceutical preparation according to the invention can therefore also advantageously comprise: The moisturizing and / or moisture retaining substances or regulators may include: sodium lactate Urea, urea derivatives, alcohols, glycerol, diols such as propylene glycol Recall, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-Decanediol or a mixture of said diols, in particular 1,2-hexanediol and and 1,2-octanediol, collagen, elastin or hyaluronic acid, Diacyl adipate, petrolatum, urocanic acid, lecithin, panthenol, phytanthate Lyol, lycopene, (pseudo)ceramide, glycosphingolipid, cholesterol, Fibrosterol, chitosan, chondroitin sulfate, lanolin, lanolin ester, amino Acids, alpha hydroxy acids (e.g., citric acid, lactic acid, malic acid) and their derivatives , monosaccharides, disaccharides and oligosaccharides, e.g., glucose, galactose, fructose, mannose, sugars, fructose and lactose, polysugars such as R-glucans, especially esters 1,3-1,4-β-glucan derived from barley, alpha-hydroxy fatty acids, triterpene acids, such as betulinic acid or ursolic acid, and algae extracts.

[0111] Depending on the substance, the concentration of the water retention regulator used is optimal for ready-to-use cosmetic or pharmaceutical applications. It is between 0.1 and 10% (m / m) based on the total weight of the final product, preferably between 0.5 and 5% (m / m). These data are especially relevant for the diols which are advantageously used. For example, hexylene glycol, 1,2-pentanediol, 1,2-hexanediol 1,2-octanediol and 1,2-decanediol, as well as 1,2-hexanediol. This applies to a mixture of 1,2-octanediol and 1,2-octanediol.

[0112] Cooling in compositions or cosmetic and pharmaceutical preparations containing the composition according to the invention The use of the agent can relieve itching. The preparation according to the invention is therefore particularly advantageous The composition may be combined with one or more cooling agents. Preferred individual cooling agents for use are listed below; those skilled in the art will recognize many others. can be added to this list; the listed cooling agents may be combined with each other. They can also be used as: l-menthol, d-menthol, racemic menthol, menthol Glycerol acetal (trade name: Frescolat(R) MGA), methyl lactate Menthyl lactate (trade name: Frescolat® ML; menthyl lactate is preferably l- Menthyl lactate, especially l-menthyl l-lactate, substituted menthyl-3-carboxylates amides (e.g., menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl-N -2,3-trimethylbutanamide, substituted cyclohexanecarboxamide, 3-menthoxy Menthoxypropane-1,2-diol, 2-hydroxyethyl Menthyl carbonate, 2-hydroxypropyl menthyl carbonate, N-acetyl Glycine menthyl ester, isopulegol, oxalic acid menthyl ethylamide (trade name Frescolat (registered trademark) X-cool), hydroxycarboxylic acid menthyl ester Menthyl esters (e.g., menthyl 3-hydroxybutyrate), monomenthyl succinate, 2-methyl Captocyclodecanone, Menthyl 2-pyrrolidin-5-one carboxylate, 2,3- Dihydroxy-p-menthane, 3,3,5-trimethylcyclohexanone, glycerol Tar, 3-menthyl-3,6-di- and trioxaalkanoates, 3-menthyl methyl Toxicacetate and Icilin.

[0113] Due to their specific synergistic effects, the preferred cooling agents are l-menthol, d-menthol, , racemic menthol, menthone glycerol acetal (trade name: Frescolat ( (registered trademark) MGA), menthyl lactate (preferably l-menthyl lactate, especially l-menthyl l - lactate (trade name: Frescolat® ML), substituted menthyl-3-carboxylate ruboxamides (e.g., menthyl-3-carboxylic acid N-ethylamide), 2-isopropyl -N-2,3-trimethylbutanamide, Substituted cyclohexanecarboxamide, 3-methyl Toxopropane-1,2-diol, 2-hydroxyethyl menthyl carbonate, 2- Hydroxypropyl menthyl carbonate, oxalic acid menthyl ethyl amide (trade name: F rescolat® X-cool), and isopulegol.

[0114] Particularly preferred cooling agents are l-menthol, racemic menthol, menthone glycerol Acetal (trade name: Frescolat® MGA), menthyl lactate (preferred or l-menthyl lactate, especially l-menthyl l-lactate (trade name: Frescolat (registered trademark: ML), oxalic acid menthyl ethylamide (trade name: Frescolat X-cool, 3-menthoxypropane-1,2-diol, 2-hydroxy Ethyl menthyl carbonate and 2-hydroxypropyl menthyl carbonate. .

[0115] Very particularly preferred cooling agents are l-menthol, menthone glycerol acetal ( Trade name: Frescolat® MGA) and menthyl lactate (preferably l- Menthyl lactate, especially l-menthyl l-lactate (trade name: Frescolat®) The mark is ML.

[0116] Depending on the substance, the concentration of the freshener used may vary depending on the composition of the ready-to-use cosmetic or pharmaceutical product. Preferably, the content is between 0.01 and 20% by weight, more preferably between 0.1 and 20% by weight, based on the total weight of the composition. 5% by weight.

[0117] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention may also comprise one or more Or it can be used with multiple osmolytes. Examples of osmolytes include sugar alcohols (myo-inositol, mannitol, sorbitol, etc.). tert-butylamine, quaternary amines, e.g., taurine, choline, betaine, betaine glycine, ecto in, diglycerol phosphate, phosphorylcholine or glycerophosphorylcholine , amino acids, e.g., glutamine, glycine, alanine, glutamate, aspartate or proline, phosphatidylcholine, phosphatidylinositol, inorganic phosphate, and polymers of said compounds, such as proteins, peptides, polyamino acids and poly All osmolytes have a skin moisturizing effect at the same time. Yes.

[0118] Preferably, keratolytic substances can also be combined with the compositions according to the invention. The lipid-soluble compounds include a large group of alpha hydroxy acids. An acid is preferably used.

[0119] For example, for the topical cosmetic or pharmaceutical treatment of dry and / or itchy skin; In compositions or cosmetic or pharmaceutical preparations containing the composition according to the invention, in particular A high percentage of nutrients may also be beneficial in reducing transepidermal water loss due to lipophilic components. In a preferred embodiment, the cosmetic or pharmaceutical preparation comprises one or more Nutritious animal and / or vegetable fats and oils, such as olive oil, castor oil, etc. Waali oil, refined soybean oil, palm oil, sesame oil, rapeseed oil, almond oil, borage oil, Evening primrose oil, coconut oil, shea butter, jojoba oil, sperm whale oil, tallow, cow's foot oil, and lard, and optionally other nutritious components, e.g., 8 to 30 C As used herein, fatty alcohols include fatty alcohols having saturated or It can be either saturated or unsaturated and either straight chain or branched. Nutrients that can be particularly preferably combined with the mixture also include, in particular, ceramides. Ceramides are N-acylsphingols that significantly improve the water retention capacity of the stratum corneum. (fatty acid amides of sphingosine) or synthetic analogues of such lipids (so-called pseudo ceramides; phospholipids, such as soybean lecithin, egg lecithin and cephalin; and vaseline, paraffin oil and silicone oil, the latter being understood to mean Among others, dialkyl- and alkylarylsiloxanes, e.g. dimethylpolysiloxanes, and methylphenylpolysiloxanes and their alkoxylation and quaternization. Includes derivatives.

[0120] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention may also be used in combination with other It may contain an active compound that is anti-inflammatory or that exhibits anti-redness and anti-itch activity. Within this context, any anti-inflammatory active compound and any compound that relieves redness and itching and reduces inflammation and inflammation may be used. Use of active compounds suitable or customary for cosmetic and / or dermatological applications Advantageously, the anti-inflammatory active compounds used and the redness and / or itching can be reduced. The active compounds that alleviate this include steroidal anti-inflammatory substances of the corticosteroid class, e.g. Docortisone, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone, and this list can be expanded by adding other steroidal anti-inflammatory drugs. Non-steroidal anti-inflammatory drugs, such as: oxicams, e.g., piroxicam, carbamazepine or tenoxicam; salicylates such as aspirin, Disalcid (registered trademark); acetic acid derivatives, e.g., Diclofenac, Solprin® or Fendosal; fenclofenac, indomethacin, sulindac, tolmetin or clinda fenamic acids, such as mefenamic acid, meclofenamic acid, flufenamic acid or nifenamic acid Fumaric acid; propionic acid derivatives, such as ibuprofen, naproxen, benoxapro or pyrazoles, e.g., phenylbutazone, oxyphenylbutazone, phenanthroline; Blazone or azapropazone can also be used. Alternatively, natural anti-inflammatory Substances that relieve redness and / or itching may also be used. active substances, special highly active plant extract fractions, and extremely pure active substances isolated from plant extracts Chamomile, Aloe Vera, Commiphora species, Rub ia species, willow, willow grass, ginger, marigold, arnica, licorice species, Echi nacea species, Rubus species and extracts, fractions and active substances derived from pure substances, e.g. Among others, bisabolol, apigenin, apigenin-7-glucoside, gingerol, e.g. For example, [6]-gingerol, paradol, for example, [6]-paradol, boswellic acid , phytosterols, glycyrrhizin, glabridin, or licochalcone A are particularly preferred. Preparations containing histamine release inhibitors also include The composition may contain a mixture of one or more anti-inflammatory active compounds.

[0121] The compositions or cosmetic or pharmaceutical preparations containing the compositions according to the invention can also be used for preservation purposes. They may contain active compounds for the treatment of various diseases and are suitable for cosmetic and / or dermatological applications. These are either novel or conventional, and are advantageously, for example, inter alia, benzoic acid, its esters and salts; Propionic acid and its salts; Salicylic acid and its salts; 2,4-Hexanoic acid (sorbic acid) and its salts; formaldehyde and paraformaldehyde; 2-hydroxybiphenyl ethers and their salts;2-zinc sulfide pyridine N-oxide;inorganic sulfites and and bisulfite; sodium iodate; chlorobutanol; 4-hydroxybenzoic acid and and its salts and esters;Dehydroacetic acid;Formic acid;1,6-bis(4-amidino-2-bromo Mofenoxy)-n-hexane and its salts; Ethylmercury-(II)-thiosalicylic acid Sodium salts;Phenylmercury and its salts;10-Undecylenic acid and its salts;5-Amino 5-amino-1,3-bis(2-ethylhexyl)-5-methylhexahydropyrimidine; Bromo-5-nitro-1,3-dioxane; 2-Bromo-2-nitro-1,3-propane Diol;2,4-Dichlorobenzyl alcohol;N-(4-chlorophenyl)-N'- (3,4-Dichlorophenyl)urea;4-Chloro-m-cresol;2,4,4'-Trichlorophenyl Dichloro-2'-hydroxy-diphenyl ether; 4-chloro-3,5-dimethylphenyl 1,1'-methylene-bis(3-(1-hydroxymethyl-2,4-dioxy) Midazolidin-5-yl)urea; Poly(hexamethylene biguanide) hydrochloride; 2- Phenoxyethanol;Hexamethylenetetramine;1-(3-chloroallyl)-3,5 ,7-Triaza-1-azoniaadamantane chloride;1-(4-chloro-phenoxy) -1(1H-imidazol-1-yl)-3,3-dimethyl-2-butanone;1,3-Bi Benzyl(hydroxymethyl)-5,5-dimethyl-2,4-imidazolidinedione; Alcohol; Octopirox®; 1,2-Dibromo-2,4-dicyanobacterium 2,2'-methylene-bis(6-bromo-4-chloro-phenol); Bromochloro 5-Chloro-2-methyl-3(2H)-isothiazolinone and 2-methyl- 3(2H)Isothiazolinone mixed with magnesium chloride and magnesium nitrate;2- Benzyl-4-chlorophenol; 2-chloroacetamide; Chlorhexidine; Acetic acid Lorhexidine;Chlorhexidine gluconate;Chlorhexidine hydrochloride;1-phenoxy -Propan-2-ol; N-Alkyl (C12-C22) trimethylammonium bromine Amides and chlorides;4,4-Dimethyl-1,3-oxazolidine;N-Hydroxymethyl N-(1,3-di(hydroxymethyl)-2,5-dioxoimidazolidine-4-yl) 1,6-Bis(4-amidinophenoxy)-n- Hexane and its salts; Glutaraldehyde 5-ethyl-1-aza-3,7-dioxabi Cyclo(3.3.0)octane; 3-(4-chlorophenoxy)-1,2-propanediol Alkyl(C8-C18)dimethylbenzylammonium chloride; Alkyl (C8-C18) dimethylbenzylammonium bromide; Alkyl (C8-C1 8) Dimethylbenzylammonium saccharinate; benzylhemiformal; 3-iodo butylcarbamate; or sodium ((hydroxymethyl)amine Any preservative selected from the group consisting of preservatives such as acetate can be used. Cut.

[0122] Other antibacterial or antifungal active substances may also be used in compositions or compositions containing the composition according to the invention. It can be particularly advantageously used in cosmetic and / or pharmaceutical preparations. The present invention may be applied to a skin disease by using any antibacterial or antifungal active substance that is suitable or customary for use in the treatment of skin diseases. In addition to the large group of conventional antibiotics, other products of interest here include cosmetic Related to products such as triclosan, climbazole, octoxyglycerin, among others , Octopirox® (1-hydroxy-4-methyl-6-(2,4,4- (trimethylpentyl)-2(1H)-pyridone 2-aminoethanol salt), chitosan, farnesol, glycerol monolaurate or a combination of the above substances. is used inter alia against underarm odor, foot odor or dandruff.

[0123] Compositions or cosmetic and / or pharmaceutical preparations containing the composition according to the invention may also be It may also contain one or more analgesic substances and may be used in cosmetics and / or pharmaceuticals. Any analgesic substance suitable or customary for the application, e.g., alpha-bisabolol, azide Glycyrrhetinic acid, guaiazulene, 18-β-glycyrrhetinic acid, allantoin, aloe vera juice Extract of Hamamelis virginiana (Witch Hazel) or gel, Ec hinacea species, Centella asiatica, chamomile, Arnica monatana, Glycyrrhiza species, algae, seaweed and Calendula o fficinalis, and vegetable oils, e.g., sweet almond oil, baobab oil, o Leaf Oil, Panthenol, Laureth-9, Trideceth-9 and 4-t-Butylcyclohexylglycerin Xanol can be used.

[0124] In addition, the composition or cosmetic or pharmaceutical preparation according to the invention may also be used to reduce body odor. It is particularly advantageous to use it in combination with active compounds that inhibit sweating (antiperspirants) to control The antiperspirant active compounds used are in particular aluminium salts, e.g. aluminium chloride. However, zinc, manium, chlorohydrate, nitrate, sulfate, acetate, etc. The use of magnesium or zirconium compounds may also be advantageous. Aluminum salts and and, to a somewhat lesser extent, aluminum / zirconium salt combinations have been shown to be effective in cosmetic applications. It has proven useful in antiperspirants and dermatological antiperspirants. The modified aluminum hydroxychloride is better tolerated by the skin but less effective. It should also be noted that substances other than aluminum salts may also be used. For example, (a) protein precipitates that cause the surface of the sweat glands to close, e.g. However, it does not contain formaldehyde, glutaraldehyde, natural and synthetic tanning agents and trimethylsiloxane. (b) dilute solutions of local anesthetics, such as lidocaine, prilocaine or It contains a mixture of these compounds, which switches on the sympathetic nerve supply to the sweat glands by blocking peripheral nerve pathways. (c) zeolites of type X, A or Y, which are effective in reducing sweat secretion and adsorbing malodours. and (d) botulinum toxin (which acts as a cytotoxic agent against the bacteria Chlostridium botulinum toxin), hyperhidrosis (pathological increase in sweat secretion), Its action is based on irreversible blocking of the release of acetylcholine, a transmitter involved in sweat secretion.

[0125] Combinations with (metal) chelating agents may also be used in the compositions or compositions containing the compositions according to the invention. It may be advantageous in cosmetic or pharmaceutical preparations, and may be used in cosmetics and / or dermatological applications. Any metal chelating agent suitable or conventional for the intended application may be used. As metal chelating agents, α-hydroxy fatty acids, phytic acid, lactoferrin, α -Hydroxy acids, such as gluconic acid, glyceric acid, glycolic acid, isoenic acid, among others Acid, citric acid, lactic acid, malic acid, mandelic acid, tartaric acid, as well as humic acid, bile acid, bile Extracts, bilirubin, biliverdin or EDTA, EGTA and their derivatives Some examples include:

[0126] Compositions or cosmetic or pharmaceutical preparations containing the compositions according to the invention for use is applied in a sufficient amount to the skin, scalp and hair in a manner customary for cosmetic and dermatological products. In this context, the composition according to the invention is applied to the hair and / or nails. Cosmetic and dermatological preparations that additionally act as anti-aging agents offer particular advantages. Advantageously, these preparations contain at least one UVA filter and / or at least one In this context, the composition contains at least one UVB filter and / or at least one inorganic pigment. and the preparations can be, for example, of this type, such as solutions, water-in-oil (W / O) emulsions, Oil-in-water (O / W) emulsions or multiple emulsions, e.g., water-in-oil-in-water (W / O / W) Typically used for emulsions, gels, hydrodispersions, solid sticks or aerosols The method can take a variety of forms.

[0127] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention is preferably in the UVB range. In combination with a substance that absorbs UV radiation in the UV range, the total amount of filter material is For example, 0.01 to 40% (m / m), preferably 0.1 to 10 % (m / m), especially 1.0-5.0% (m / m), which protects hair and hair from ultraviolet rays in all ranges. These can provide cosmetic preparations that protect the hair and / or the skin. The preparations according to the invention can also function as sunscreens. When present, these may be oil-soluble or water-soluble. VB filters include: 3-benzylidene camphor derivatives, preferably 3-(4-methylbenzylidene)camphor, 3-benzylidenecamphor; 4-amino benzoic acid derivatives, preferably 2-ethylhexyl 4-(dimethylamino)benzoate, Amyl 4-(dimethylamino)benzoate; cinnamic acid esters, preferably 2-ethylhexyl Xyl 4-methoxycinnamate, isopentyl 4-methoxycinnamate; salicylic acid Esters, preferably 2-ethylhexyl salicylate, 4-isopropyl benzyl salicylate salicylate homomenthyl; derivatives of benzophenone, preferably 2-hydroxy- 4-Methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone Non, 2,2'-dihydroxy-4-methoxybenzophenone; benzalmalonic acid ester 2,4,6 -Trianilino-(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5- Triazines. Advantageous water-soluble UVB filters include 2-phenylbenzimidazole- Salts of 5-sulfonic acids, for example their sodium, potassium or triethanolamine salts. sulfonic acid derivatives of benzophenone, preferably 2-Hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts; 3- Sulfonic acid derivatives of benzylidene camphor, e.g., 4-(2-oxo-3-bornyl 2-Methyl-5-(2-oxo-3-bornylidene-)benzenesulfonic acid methyl)sulfonic acid and their salts, as well as 1,4-di(2-oxo-10-sulfo- 3-bornylidenemethyl)-benzene and its salts (corresponding 10-sulfato compounds, for example, the corresponding sodium, potassium and triethanolammonium salts), and Benzene-1,4-di(2-oxo-3-bornylidenemethyl-10-sulfonic acid) is an example. can be done.

[0128] UVA filters, such as those commonly contained in cosmetic preparations, are used. These substances are preferably derivatives of dibenzoylmethane, especially 1-(4'-tert-butylphenyl)-3-(4'-methoxyphenyl)propane- 1,3-Dione and 1-phenyl-3-(4'-isopropylphenyl)propane-1 ,3-dione. The amounts used for the UVB combination can be similar. .

[0129] The compositions or cosmetic or pharmaceutical preparations containing the composition according to the invention also advantageously These may, for example, contain other auxiliary substances or excipients normally used in such preparations, such as antioxidants. Colouring agents, perfume oils, defoaming agents, colouring agents, pigments with colouring action, thickeners, surface-active substances, emulsifiers, Plasticizing substances, moisturizing and / or moisture-retaining substances, fats, oils, waxes or cosmetic preparations Other conventional constituents of the product, such as alcohols, polyols, polymers, foam stabilizers, electrolytes, etc. It can be combined with substances, organic solvents or silicone derivatives. The present invention may be used in combination with any imaginable antioxidant, balm, or detergent that is suitable or customary for use in dermatological applications. Foaming agents, coloring agents, pigments with coloring action, thickeners, surface-active substances, emulsifiers, plasticizing substances, moisturizing agents, Moisturizing and / or moisture-retaining substances, fats, oils, waxes, alcohols, polyols, poly The polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives used herein according to the invention are It is possible.

[0130] The high content of treatment substances is useful in the preparation of the present invention for topical, preventive or cosmetic treatment of the skin. It is generally advantageous in preparations containing the compositions according to the invention. The composition may comprise one or more animal and / or vegetable processed fats and oils, e.g., olive oil. Oil, sunflower oil, refined soybean oil, palm oil, sesame oil, rapeseed oil, almond oil, le Rijn oil, evening primrose oil, coconut oil, shea butter, jojoba oil, sperm whale oil, beef tallow, Cow foot oil and lard, and optionally other treated constituents, such as C8-C30 aliphatic As used herein, the fatty alcohol may be saturated or unsaturated and A linear or branched aliphatic alcohol, examples of which include decanol, decenol, octadecyl alcohol, nol, octenol, dodecanol, dodecenol, octadienol, decadienol Alcohol, dodecadienol, oleyl alcohol, ricinoleyl alcohol, erucic alcohol Alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol Alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, caprylic Alcohol, linoleyl alcohol, linolenyl alcohol and behenyl alcohol The list may include, for example, the following alcohols: In some cases, this can be expanded to include other structurally and chemically related alcohols. The fatty alcohols are preferably derived from naturally occurring fatty acids, usually from the corresponding esters of the fatty acids. Prepared by reduction. Aliphatic acids formed by reduction from naturally occurring fats and fatty oils. Alcohol fractions, e.g. beef tallow, peanut oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil , palm kernel oil, linseed oil, corn oil, castor oil, rapeseed oil, sesame oil, cocoa butter And cocoa fat can also be used.

[0131] Treatment substances which may be preferably combined with the compositions according to the invention include also: Examples include: ceramides, what are thought to be N-acylsphingosines (sphingosines) fatty acid amides of vingosine) or synthetic analogues of such lipids (so-called pseudoceramides ), which significantly improve the water-retaining capacity of the stratum corneum; phospholipids, e.g. soybean residues tin, egg lecithin and cephalin; vaseline, paraffin and silicone oil The latter are, inter alia, dialkyl- and alkylaryl-siloxanes, e.g., dimethylpolysiloxanes. Polysiloxanes and methylphenylpolysiloxanes, as well as their alkoxylated derivatives. and quaternized derivatives.

[0132] Hydrolyzed animal and / or vegetable proteins may also be included in the composition according to the invention. In this connection, particularly elastin, collagen, collagen fibres and collagen fibres can be advantageously added to the preparation. Lagen, keratin, milk protein, soy protein, oat protein, bean tan Protein, almond protein and wheat protein fraction or corresponding hydrolyzed protein These include proteins and their condensation products with fatty acids, as well as quaternized hydrolyzed proteins. Preferably, hydrolyzed vegetable proteins are used.

[0133] Cosmetic or dermatological preparations containing the compositions according to the invention are solutions or lotions. where R is an integer from 1 to 3, solvents that can be used include: water or aqueous solutions; fats Oils, fats, waxes and other natural and synthetic fatty bodies, preferably fatty acids and low carbon numbers Esters with alcohols having the formula: isopropanol, propylene glycol or The esters are either glycerol or fatty alcohols with low carbon number alkanoic acids. or fatty acid esters; alcohols, diols or polyols with low carbon numbers and and their ethers, preferably ethanol, isopropanol, propylene glycol , glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, di Ethylene glycol monomethyl or monoethyl ether and similar products. In particular, mixtures of alcoholic solvents are used. In the case of alcoholic solvents, water is an additional constituent. can be done.

[0134] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention also has an antioxidant effect. The composition may also contain colorants suitable or customary for cosmetic and / or dermatological applications. Any antioxidant that is suitable for use in the present invention may be used. Advantageously, the antioxidant is an amino acid (e.g., lysine, histidine, tyrosine, tryptophan) and their derivatives, imidazole (e.g. urocanic acid) and their derivatives, peptides, e.g. D,L-carnosine , D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids oids, carotenes (e.g. α-carotene, β-carotene, lycopene) and their derivatives Lipoic acid and its derivatives (e.g. dihydrolipoic acid), gold thioglucose, propylthio Auracil and other thiols (e.g., thioredoxin, glutathione, cysteine, Cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, and proline Pyryl, amyl, butyl and lauryl, palmitoyl, oleyl, gamma-linoleyl, cholesteryl steryl and glyceryl esters) and their salts, dilauryl thiodipropionate , distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfonates Sulfoximine compounds (e.g. buthionine sulfoximine, homocysteine ​​sulfoximine, thionine sulfone, penta-, hexa-, and hepta-thionine sulfoximine) (these are at very low tolerated doses), as well as (metal) chelating agents, e.g. alpha-hydroxy fats acid, palmitic acid, phytic acid, lactoferrin, α-hydroxy acids (e.g. citric acid, Lactic acid, malic acid), humic acid, bile acid, bile extract, bilirubin, biliverdin, EDT A, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g., γ- nolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinone vitamin C and its derivatives (e.g., aspartate palmitate) Ascorbyl, Magnesium Ascorbyl Phosphate, Ascorbyl Acetate), Tocopherol and their derivatives (e.g., vitamin E acetate), vitamin A and its derivatives body (e.g. vitamin A palmitate), and also coniferyl benzoate from benzoin resin Salts, rutin acid and its derivatives, ferrulic acid and its Derivatives, butyl hydroxytoluene, butyl hydroxyanisole, nordihydroguaia Acetic acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (e.g., ZnO, Zn SO4), selenium and its derivatives (e.g., selenium methionine), stilbene and Their derivatives (e.g., stilbene oxide, trans-stilbene oxide), and derivatives of the active compounds (e.g., salts, esters, ethers, sugars, nucleotides, nucleosides, etc.) nucleotides, peptides and lipids), for example from the group consisting of those suitable according to the present invention. are selected.

[0135] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention also contains vitamin They may also contain vitamins and vitamin precursors, making them suitable for cosmetic and / or dermatological applications. Any vitamins and vitamin precursors suitable or customary for use in the art may be used. Vitamins and vitamin precursors, e.g., tocopherols, vitamin A, nicotinic acid and nicotinamide, other B-complex vitamins, especially biotin, and vitamin C. Other examples of this group which are preferably used include pantothecin. Thaylene alcohol and its derivatives, especially its esters and ethers, and cathi Derivatives of pantothenyl alcohol obtained organically, e.g., pantothenyl alcohol Triacetate, pantothenyl alcohol monoethyl ether and its monoacetate and also cationic pantothenyl alcohol derivatives.

[0136] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention may also be used for whitening. These may contain active compounds having a specific action and are useful in cosmetic and / or dermatological applications. Any whitening active compound suitable or conventional for use in skin whitening may be used in accordance with the present invention. Advantageous whitening active compounds in this context include, inter alia, whitening stilbene derivatives, Ujic Acid, Hydroquinone, Arbutin, Ascorbic Acid, Magnesium Ascorbyl Phosphate , resorcinol, licorice root extract and their constituents glabridin or lycosides Chalcone A, or extracts from Rumex and Ramulus species, pine species (Pinus) or an extract from Vitis species.

[0137] Compositions or cosmetic preparations containing the composition according to the invention may also have a skin tanning action. and in cosmetic and / or dermatological applications, Any suitable or conventional skin tanning active compound may be used. Acetone (DHA; 1,3-dihydroxy-2-propanone) is used as an example here. DHA may be provided in either monomeric or dimeric form. A proportion of the dimer is predominant in the crystalline form.

[0138] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention may also contain monosaccharides. , disaccharides and oligosaccharides, e.g., glucose, galactose, fructose, mannose It may also contain sugar and lactose.

[0139] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention may also be prepared by adding a plant extract. They may also contain extracts, which are usually prepared by extracting the whole plant. In individual cases, the extracts were prepared solely from the flowers and / or leaves, wood, bark or roots of the plant. With regard to the plant extracts which can be used according to the invention, see in particular Leitfade n zur Inhaltsstoffdeklaration kosmetisch er Mittel(Guide to the Declaration of Co. nstituents of Cosmetic Agents), Industries Verband Korperpflegemittel und Waschmitt el eV(IKW)(Industrial Association for Toiletries and Detergents, Frankfurt, 3rd edition. See the extracts listed in the table beginning on page 44. Particularly advantageous extracts include: Aloe, Hamamelis, Algae, Oak Bark, Willow Herb, Nettle, Lamium, Hops, chamomile, yarrow, arnica, calendula, burdock root, horsetail, sunflower Zashi, linden blossom, cucumber, almond, pine needles, horse chestnut, sandalwood Juniper, coconut, mango, apricot, orange, lemon, lime, grapefruit Roots, apples, green tea, grapefruit seeds, wheat, oats, barley, sage, ta Imu, basil, rosemary, birch, mallow, cardamom, willow bark, hawthorn These include moss, coltsfoot, velvet mallow, ginseng and ginger root. Among these, particularly preferred extracts include aloe vera, chamomile, algae, and rosemary. Calendula, ginseng, cucumber, sage, nettle, linden blossom, Lungica and Hamamelis. Mixtures of two or more plant extracts are also useful. The extraction agent that can be used to prepare the plant extract is Examples of suitable alcohols include water, alcohols and mixtures thereof. Alcohols are lower alcohols, e.g., ethanol and isopropanol, but polyhydric alcohols. Alcohols, such as ethylene glycol, propylene glycol and butylene glycol Also preferred is ethanol, both as the sole extractant and in a mixture with water. According to the present invention, the plant extract can be used in pure or diluted form. do.

[0140] The compositions or cosmetic or pharmaceutical preparations containing the composition according to the invention also include, in particular Crystalline or microcrystalline solids, such as inorganic micropigments, are incorporated into the preparations according to the invention. If used, they may contain anionic, cationic, nonionic and / or amphoteric surfactants. Surfactants are amphiphilic compounds that can dissolve organic, non-polar substances in water. Surfactants are generally classified according to the nature and charge of the hydrophilic portion of the molecule. Four groups can be distinguished here: anionic surfactants, cationic surfactants, both Ionic and nonionic surfactants.

[0141] Anionic surfactants usually contain carboxylate, sulfate or sulfonate groups. In aqueous solution, they form negatively charged organic imines in acidic or neutral media. Cationic surfactants are mostly based on the presence of a quaternary ammonium group. In aqueous solution, they form positively charged organic imines in acidic or neutral media. Amphoteric surfactants contain both anionic and cationic groups, but Depending on the pH value, they behave like anionic or cationic surfactants in aqueous solution. They carry a positive charge in a strongly acidic medium and a negative charge in an alkaline medium. In the pH range, by contrast, they are zwitterions. Polyether chains form non-ionic interfaces. Typical of active agents: Nonionic surfactants do not form ions in aqueous media.

[0142] Anionic surfactants which can be used advantageously include: acyla amino acids (and their salts), e.g., acyl glutamates, e.g., acyl glutamic acid Sodium, Di-TEA-Palmitoyl Aspartate and Caprylic / Capric Glycol sodium glutamate; acyl peptides, e.g. palmitoyl hydrolyzed milk protein, co Sodium Cocoyl Hydrolyzed Soy Protein and Sodium Cocoyl Hydrolyzed Collagen Calcium / potassium; Sarcosinates, e.g., myristoyl sarcosine, lauroyl sarcosine TEA, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate; taurates, such as sodium lauroyl taurate and sodium methyl cocoyl taurate acyl lactylate, for example lauroyl lactylate and caproyl lactylate; Laninates; carboxylic acids and derivatives, e.g., lauric acid, aluminum stearate , magnesium alkanolates and zinc undecylates; ester carboxylic acids, e.g. Calcium Stearoyl Lactylate, Laureth-6 Citrate and PEG-4 Laureth Sodium myrocarboxylate; ether carboxylic acids, such as sodium laureth-13 carboxylate sodium and sodium PEG-6 cocamide carboxylate; phosphate esters and salts, e.g. For example, DEA-oleth-10 phosphate and dilaureth-4 phosphate; sulfonic acids and Salts, e.g., acyl isethionates, e.g., sodium / ammonium cocoyl isethionate alkyl aryl sulfonates; alkyl sulfonates, e.g., coco monoglycerides Sodium sulfonate, Sodium olefin (C12-14) sulfonate, Lauryl sulfonate Sodium fumarate and PEG-3 cocamide magnesium sulfate; sulfosuccinates, e.g. For example, dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, Disodium Lauryl Sulfosuccinate and Undecylenamide MEA-2 sodium; and sulfates, e.g., alkyl ether sulfates, e.g., laureth sulfate. Sodium Laureth Sulfate, Ammonium Laureth Sulfate, Magnesium Laureth Sulfate, M Laureth Sulfate IPA, TIPA Laureth Sulfate, Sodium Myreth Sulfate and C12-13 Sodium Pareth Sulfate and alkyl sulfates, such as sodium lauryl sulfate, ammonium lauryl sulfate, Sodium and TEA Lauryl Sulfate.

[0143] Cationic surfactants which can be advantageously used include alkylamines, alkyl These include imidazoles, ethoxylated amines and quaternary surfactants.

[0144] Quaternary surfactants are surfactants that contain at least one alkyl group covalently bonded to four alkyl or aryl groups. Contains N atoms, which results in a positive charge regardless of the pH value. Alkyl betaines, Alkylamidopropyl betaine and alkylamidopropyl hydroxysulfane ( The cationic surfactant used is preferably Also preferred are the group of quaternary ammonium compounds, in particular benzyltrialkylammonium chlorides. ammonium or benzyltrialkylammonium bromide, for example benzyldimethylsulfonium chloride Tearyl ammonium, as well as alkyl trialkyl ammonium salts, such as cetearyl chloride. Cetyltrimethylammonium bromide or cetyltrimethylammonium bromide, alkyldichloride Methyl hydroxyethyl ammonium or alkyl dimethyl hydroxyethyl ammonium bromide ammonium, dialkyldimethylammonium chloride or dialkyldimethylammonium bromide ammonium, alkylamidoethyltrimethylammonium ether sulfate, alkylpi pyridinium salts, such as laurylpyridinium chloride or cetylpyridinium chloride, imidazolium chloride, Zoline derivatives and compounds of cationic nature, such as amine oxides, e.g. alkyl Selected from alkyl dimethylamine oxide or alkylaminoethyl dimethylamine oxide Cetyltrimethylammonium salts can be used with particular advantage. .

[0145] Amphoteric surfactants which can be advantageously used include acyl / dialkylethylene diamines. amines, such as sodium acylamphoacetate, disodium acylamphodipropionate, Disodium alkylamphodiacetate, sodium amphohydroxypropyl acylsulfonate um, disodium acylamphodiacetate and sodium acylamphopropionate;N -Alkylamino acids, e.g. aminopropyl alkylglutamides, alkylaminopropyl ionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglyceryl Nate is one example.

[0146] Nonionic surfactants which can be advantageously used are: alcohols; alkanols Amides, e.g. cocamide MEA / DEA / MIPA, amine oxides, e.g. cocoa amidopropylamine oxide; ethylene oxide of carboxylic acids, glycerol, sorbitan or or other alcohols; ethers, e.g. Ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated propoxylated glycerol esters, ethoxylated / propoxylated cholesterol, ethoxy Ethoxylated / Propoxylated Triglyceride Esters, Ethoxylated / Propoxylated Lanolin, Ethoxylated Polysiloxanes, propoxylated POE ethers and alkyl polyglyoxanes Glycosides, such as lauryl glucoside, decyl glucoside and coconut glucoside; glycerol esters and ethers; polyglycerol esters, diglycerol esters, Monoglycerol esters; methylglucose esters; esters of hydroxy acids. can be done.

[0147] Anionic and / or amphoteric surfactants and one or more nonionic surfactants The use of a surfactant in combination with the histamine release inhibitor according to the invention is also advantageous. In preparations containing the agent, at a concentration between 1 and 98% (m / m) based on the dry weight of the preparation It can exist.

[0148] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention is for topical use. The formulation may be in a form suitable for use, for example, a lotion, an aqueous or aqueous-alcoholic gel, a vesicle, As a dispersion or as a simple or complex emulsion (O / W, W / O, O / W / O or W / O / W), liquid, semi-liquid or solid, e.g. milk, cream, gel, cream It can also be formulated into a gel, paste or stick, optionally with It may be packaged as an azole and may take the form of a mousse or spray. These compositions are prepared according to the usual methods.

[0149] To prepare an emulsion, the oily phase can be advantageously selected from the following group of substances: Oils, mineral waxes; fatty oils, fats, waxes and other natural and synthetic fatty bodies, preferably Preferably, fatty acids and alcohols having low carbon numbers, such as isopropanol, propylene Esters with glycols or glycerol, or with fatty alcohols and low carbon numbers esters of alkanoic or fatty acids having the formula: alkyl benzoates; silicone oils; For example, dimethylpolysiloxane, diethylpolysiloxane, diphenylpolysiloxane and mixed forms thereof. Advantageously, saturated and / or non-saturated cyclic alkyl esters with a chain length of 3 to 30 C atoms. or unsaturated, branched and / or linear alkane carboxylic acids with a chain length of 3 to 30 C atoms Esters with saturated and / or unsaturated, branched and / or straight chain alcohols having aromatic carboxylic acids and saturated and / or unsaturated carboxylic acids with a chain length of 3 to 30 C atoms It is possible to use from the group of esters with cyclic, branched and / or linear alcohols. Preferred ester oils include isopropyl myristate, isopropyl palmitate, Isopropyl stearate, isopropyl oleate, n-butyl stearate, n-Hexyl oleate, n-decyl oleate, isooctyl stearate, stearyl Isononyl isononanoate, 2-ethylhexyl palmitate, 2-ethylhexyl isononate 2-Hexyl laurate, 2-Hexyldecyl stearate, 2-Octyl palmitate Decyl, Oleyl Oleate, Oleyl Erucate, Erucyl Oleate, Erucyl Erucate and synthetic, semi-synthetic and natural mixtures of such esters, e.g., jojoba oil. can be done.

[0150] The oil phase may also include branched and straight chain hydrocarbons and waxes, silicone oils, dialkyl ethers, The group includes esters, saturated or unsaturated, branched or straight chain alcohols, and fatty acid triglycerides. and in particular saturated and / or triglycerol esters of unsaturated, branched and / or linear alkane carboxylic acids The fatty acid triglycerides may be advantageously selected from synthetic, semi-synthetic and and natural oils, such as olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, aloe vera oil, It may be advantageously selected from the group comprising mond oil, palm oil, coconut oil, palm kernel oil, etc. Any blend of such oil and wax components may also be used to advantage. In some cases, a wax, e.g., cetyl palmitate, is used as the only lipid component of the oil phase. It is also advantageous to use 2-ethylhexyl isostearate, octyl Dodecanol, isotridecyl isononanoate, isoeicosane, 2-coconut oil fatty acid ethylene C12-15 alkyl benzoate, caprylic / capric triglyceride and dicaprylyl ether. Mixture of alkyl and 2-ethylhexyl isostearate, C12-15 alkyl benzoate and isotridecyl isononanoate, and a mixture of C12-15 alkyl benzoate, 2 A mixture of ethylhexyl isostearate and isotridecyl isononanoate is particularly The hydrocarbons paraffin oil, squalane and squalene are also advantageously used. The oil phase may also advantageously contain or contain a cyclic or linear silicone oil. It can also consist entirely of one or more silicone oils, as well as other oil phase structures. Additional contents of the ingredient are preferably used. Cyclomethicone (e.g., decamethylcyclomethicone). Cloptasiloxane can be advantageously used as the silicone oil. Silicone oils such as undecamethylcyclotrisiloxane, polydimethylsiloxane, Poly(methylphenylsiloxane) and poly(methylphenylsiloxane) can also be used advantageously. methicone and isotridecyl isononanoate, and cyclomethicone and 2-ethylhexyl Mixtures of isostearate are also particularly advantageous.

[0151] As the aqueous phase of a preparation containing the composition according to the invention and provided in the form of an emulsion, and ethers thereof, preferably Ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol ethylene glycol monoethyl or monobutyl ether, propylene glycol Monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or or monoethyl ether and similar products, as well as alcohols with low C numbers, e.g. For example, ethanol, isopropanol, 1,2-propanediol, glycerol and In particular, one or more thickening agents may be mentioned, such as silicon dioxide, aluminum silicate, etc. The group including polysaccharides and their derivatives, e.g., hyaluronic acid, xanthan gum , hydroxypropyl methylcellulose, particularly preferably from the group comprising polyacrylates, preferably Preferably, polyacrylates from the group containing the so-called Carbopol, e.g. Carbopol Models 980, 981, 1382, 2984, and 5984, each of which may be used by itself or in combination. In combination, these can be advantageously selected.

[0152] A composition or cosmetic or pharmaceutical composition provided in the form of an emulsion containing the composition according to the present invention. The cosmetic preparations are those commonly used in the art for preparing cosmetic or pharmaceutical preparations. The emulsion advantageously contains one or more emulsifiers.

[0153] The composition or cosmetic or pharmaceutical preparation containing the composition according to the invention may also be used as a cosmetic agent. Commercially or pharma- ceutically acceptable carriers, such as those commonly used in the art, It may contain one of the following sugars: lactose, glucose, sucrose, cellulose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, Alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolide , Cellulose, Water, Syrup, Methylcellulose, Methylhydroxybenzoate, Propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc. The product or pharmaceutical preparation may also contain, in addition to the above components, lubricants, wetting agents, sweeteners, flavoring agents, Suitable pharma- ceutically acceptable carriers and The preparations are described in Remington's Pharmaceutical Sciences. s (19th ed., 1995).

[0154] Pharmaceutical preparations may be administered topically, orally or parenterally.

[0155] The appropriate dose of the pharmaceutical preparation according to the invention may be determined, for example, according to age, weight, sex or disease. It depends on factors such as the condition causing the drug, food, time of administration, route of administration, rate of excretion and patient sensitivity. It can be formulated in various ways depending on the needs.

[0156] The pharmaceutical compositions according to the present invention can be prepared in unit dosage form and can be easily and conveniently administered by one of ordinary skill in the art to which the present invention pertains. The method can be easily carried out using pharma- ceutically acceptable carriers and / or excipients. The composition may be prepared by preparing a formulation.

[0157] In a further aspect, the present invention provides an avenanthramide or an analog thereof, or an avenant. avenanthramide or its analogues, in particular avenanthramide A or avenanthramide L or 4-Hydroxyavenanthramide D for improving the solubility of compositions containing it Regarding the use of cetophenone.

[0158] Finally, the present invention relates to a composition comprising at least one avenanthramide or avenanthramide. avenanthramide analogue compound, preferably avenanthramide A or avenanthramide L or di A method for improving the solubility of hydroavenanthramide D, comprising: The present invention relates to a method of adding tofenone to a composition.

[0159] Although the present invention has been specifically shown and described with reference to preferred embodiments, and various changes in form and detail may be made without departing from the scope of the present invention. Moreover, the present invention is intended to cover all possible variations thereof. Unless specifically indicated otherwise, any combination of the above-described elements may be used. Includes.

[0160] In addition, while features or aspects of the invention are described in terms of Markush groups, those of skill in the art will appreciate that The present invention also relates to any individual member or subgroup of members of the Markush group. I am aware of what is stated here in this regard.

[0161] The present invention will now be described in detail with reference to the following examples, which are merely illustrative of the present invention. The invention is not limited by or to the following examples, which are merely illustrative of the invention. This is not to be the case. EXAMPLES

[0162] Example 1: Avenanthramides A, B, C, D or L and Dihydroavenanthramide D Effect of 4-hydroxyacetophenone on the solubility of

[0163] Avenanthrami in solution, combined with 4-hydroxyacetophenone at different concentrations The solubility of dihydroavenanthramides A, B, C, D or L and dihydroavenanthramide D was investigated using 4-hydroxyavenanthramides. The results were evaluated for solutions of avenanthramides A, B, C, D and L that did not contain acetophenone. It was worth it.

[0164] The corresponding avenanthramide was pre-dissolved in ethanol or glycol. Water and 4-hydroxyacetophenone were added while stirring and heating to 60°C. The appearance of the solutions was evaluated at 22° C. according to Table 1:

[0165] [Table 2]

[0166] [Table 3]

[0167] The appearance of the different solutions is shown in FIG. Table 4: Solutions containing avenanthramide L [Table 4-a] Increasing the concentration of 4-hydroxyacetophenone improved the solubility of Avn L. As shown in Table 4b, when the concentration was further increased to 0.5%, By increasing the temperature, a clear solution was obtained. [Table 4-b]

[0168] The appearance of the different solutions is shown in Figures 2a and 2b.

[0169] [Table 5]

[0170] The appearance of the different solutions is shown in FIG.

[0171] [Table 6]

[0172] The appearance of the different solutions is shown in FIG.

[0173] Table 7: Solutions containing dihydroavenanthramide D [Table 7-a]

[0174] The appearance of the different solutions is shown in Figure 5a. [Table 7-b] The appearance of the different solutions is shown in Figure 5b.

[0175] [Table 8]

[0176] Addition of 4-hydroxyacetone to avenanthramide or dihydroavenanthramide D solution As shown in Tables 3 to 7, the addition of phenol results in a clearer solution with less precipitation. The results clearly show this.

[0177] In particular, the 4 The addition of 0.1 or 0.5 wt. % hydroxyacetophenone resulted in no significant difference in turbidity or A clear solution results without precipitate.

[0178] In addition, the addition of 0.05% of 4-hydroxyacetophenone to the dihydroavenanthramide D solution was Additions at concentrations between 0.5 and 1.0% (Tables 7a and 7b) produced clear solutions without turbidity or precipitate. Brings liquid.

[0179] The preferred ratio of avenanthramide to 4-hydroxyacetophenone is 1:1 to 1 The preferred ratio is 1:1.5 to 1:40. The ratio of ensulamide D to 4-hydroxyacetophenone is 1:0.2 to 1:2. The results in Table 8 also show that a more preferred ratio is 1:0.5.

[0180] Example 2: Formulation examples

[0181] [Table 9-1] [Table 9-2]

[0182] [Table 10]

[0183] [Table 11]

[0184] [Table 12]

[0185] [Table 13]

[0186] The perfume oils PO1, PO2, PO3, PO4, or PO5 are prepared separately in each case. The preparations / formulations presented below were obtained.

[0187] Cosmetic preparations / formulations (amounts in % by weight of total preparations / formulations)

[0188] [Table 14]

[0189] [Table 15]

[0190] [Table 16-1] [Table 16-2]

[0191] [Table 17-1] [Table 17-2]

[0192] [Table 18]

[0193] [Table 19]

[0194] [Table 20]

[0195] [Table 21-1] [Table 21-2]

[0196]

Table 22-1

Table 22-2

[0197]

Table 23-1

Table 23-2

[0198]

Table 24-1

Table 24-2

[0199]

Table 25-1

Table 25-2

[0200]

Table 26-1

Table 26-2

[0201]

Table 27

[0202]

Table 28

[0203]

Table 29

[0204]

Table 30

[0205]

Table 31

[0206]

Table 32

[0207]

Table 33

[0208]

Table 34

[0209]

Table 35

Table 36

[0210]

Table 37

[0211]

Table 38

[0212]

Table 39

[0213]

Table 40

[0214]

Table 41

[0215]

Table 42

[0216]

Table 43

[0217]

Table 44

[0218]

Table 45

[0219]

Table 46

[0220]

Table 47

[0221]

Table 48

[0222]

Table 49

[0223]

Table 50

[0224]

Table 51

[0225]

Table 52-1

Table 52-2

[0226]

Table 53-1

Table 53-2

[0227]

Table 54

[0228]

Table 55

[0229]

Table 56

[0230]

Table 57

[0231]

Table 58

[0232]

Table 59

[0233]

Table 60

[0234]

Table 61

[0235]

Table 62

[0236]

Table 63

[0237]

Table 64

[0238]

Table 65-1

Table 65-2

Table 65-3

Table 65-4

Table 65-5

Table 65-6

Table 65-7

Table 66

Table 67

Claims

1. at least one avenanthramide selected from the group consisting of avenanthramides A, B, C, G, H, K, L and R or mixtures of these avenanthramides; 4-hydroxyacetophenone; and at least one solvent or a mixture of solvents A composition comprising or consisting of:

2. 2. The composition of claim 1, wherein the at least one avenanthramide is selected from the group consisting of avenanthramide L and avenanthramide R.

3. The composition of claim 1 or 2, wherein at least one avenanthramide is avenanthramide L.

4. The composition of claim 1 , further comprising dihydroavenanthramide D.

5. 5. The composition of claim 1, wherein the at least one avenanthramide is obtained from an oat source of the species Avena sativa or Avena nuda.

6. Based on the total weight of the composition, - 0.0001 to 5.0% by weight of at least one avenanthramide; and 0.005 to 2.0% by weight of 4-hydroxyacetophenone Including, 6. The composition according to any one of claims 1 to 5.

7. 7. The composition of claim 1, wherein the ratio of the at least one avenanthramide to 4-hydroxyacetophenone is from 1:1 to 1:

50.

8. The composition according to any one of claims 1 to 7, wherein the solvent is selected from the group consisting of water, fatty oils, fats, waxes and other natural and synthetic fatty bodies.

9. 9. Non-therapeutic or cosmetic use of a composition according to any one of claims 1 to 8 for skin care, scalp care, hair care, nail care or in the prevention and / or treatment of skin conditions, sensitive skin, skin irritation, skin redness, wheals, pruritus (itching), skin aging, wrinkle formation, loss of skin volume, loss of skin elasticity, pigment spots, pigmentation disorders or dry skin, i.e. dry skin in need of skin moisturisation.

10. 9. A composition according to any one of claims 1 to 8 for use as a medicament.

11. Prevention and / or treatment of barrier-associated inflammatory, immunoallergic, atherogenic, or dry skin or keratinopathy, or Prevention and / or treatment of skin or keratinous disorders having a hyperproliferative component, or Prevention and / or treatment of skin diseases associated with increased ROS production, or in the prevention and / or treatment of cardiovascular diseases, allergic reactions, coronary heart disease, To reduce serum LDL cholesterol and lipid levels, To reduce blood pressure, To improve insulin sensitivity, and 11. The composition according to claim 10 for use in enabling control of blood glucose levels.

12. 12. The composition of claim 11, wherein the skin or keratinous disease is selected from the group consisting of eczema, psoriasis, seborrhea, dermatitis, erythema, pruritus (itching), inflammation, irritation, fibrosis, lichen planus, pityriasis rosea, tinea versicolor, autoimmune blistering diseases, urticarial, angiodermal and allergic skin reactions, and wound healing, and / or the skin disease associated with increased ROS production is selected from the group consisting of atopic dermatitis, neurodermatitis, psoriasis, rosacea, acneiform rash, asteatosis and xerosis.

13. 9. Use of a composition according to any one of claims 1 to 8 for the preparation of a food, nutraceutical, cosmetic, pharmaceutical or veterinary preparation.

14. 9. A food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation comprising a composition according to any one of claims 1 to 8.

15. 15. The composition according to any one of claims 1 to 8 or the food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation according to claim 14, further comprising one or more active substances selected from the group consisting of skin moisturizing and / or moisture-retaining substances, cooling agents, osmolytes, keratinizing substances, nutritional substances, anti-inflammatory, antibacterial or antifungal substances, substances with redness-relieving or itching-relieving action, analgesic substances, and any mixtures thereof; and / or cosmetically or pharma- ceutically acceptable excipients selected from the group consisting of antioxidants, preservatives, (metal) chelating agents, penetration enhancers, surface-active substances, emulsifiers, perfume oils, defoamers, colorants, pigments with coloring action, thickeners, plasticizers, fats, oils, waxes or other conventional constituents of cosmetic compositions, alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives, and any mixtures thereof.

16. 15. The composition according to any one of claims 1 to 8 or the food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation according to claim 14, wherein the skin moisturizing and / or moisture retaining substance is selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol and mixtures of said diols.

17. 17. The food, dietary supplement, cosmetic, pharmaceutical or veterinary preparation of any one of claims 14 or 16 provided as a liquid, tincture, lotion, emulsion, gel, cream, ointment, spray or shampoo.

18. Use of 4-hydroxyacetophenone to improve the solubility of at least one avenanthramide selected from the group consisting of avenanthramides A, B, C, G, H, K, L and R or mixtures of these avenanthramides, or an avenanthramide analog, dihydroavenanthramide D.

19. A method for improving the solubility of at least one avenanthramide selected from the group consisting of avenanthramides A, B, C, G, H, K, L and R, or mixtures of these avenanthramides, or an avenanthramide analog, dihydroavenanthramide D, in a composition comprising a solvent, comprising adding 4-hydroxyacetophenone to the composition.

20. - the avenanthramide analogue dihydroavenanthramide D; 4-hydroxyacetophenone; skin moisturizing and / or hydrating substances selected from the group consisting of 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol and mixtures of said diols; and at least one solvent or a mixture of solvents A composition comprising or consisting of:

Images